| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.2K | 1.1% | 9.5% |
| Total Income | 1.2K | 4.9% | 8.6% |
| Expenditure | 909.89 | 6.5% | 13.3% |
| PBT | 322.46 | 0.1% | 2.9% |
| Net Profit | 245.04 | 1.8% | 2.9% |
| OPM | 28.26% | 4.53pp | 4.53pp |
| NPM | 19.88% | 0.62pp | 2.36pp |
| EPS | 19.61 | 1.9% | 2.7% |
Ajanta Pharma Reports 20% Revenue Growth & 18% PAT Growth in Q3 FY 2026
30 Jan 2026 · 30 Jan, 3:05 pm
Summary
Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, reported an excellent performance for the quarter and nine months ended 31st December 2025. The company's Q3 FY 2026 performance highlights include a 20% increase in revenue from operations, a 19% increase in EBITDA, and an 18% increase in profit after tax (PAT). The 9M FY 2026 performance highlights include a 16% increase in revenue from operations and a 14% increase in PAT.
Management Comments
Ajanta Pharma Limited
Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 3% quarter and nine months ended 31st December 2025.
Informational and educational content only. Not investment advice.